Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Neoantigen-based Glioblastoma Vaccine and Poly-ICLC Vaccine in Treating Patients with Newly Diagnosed Glioblastoma

Trial Status: complete

This pilot clinical trial studies the side effects of neoantigen-based glioblastoma vaccine and poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose) vaccine and how they work in treating patients with newly diagnosed glioblastoma. Neoantigen-based glioblastoma vaccine is personalized vaccine designed to target specific mutations (changes in the deoxyribonucleic acid [DNA]) of the patient's glioblastoma tumor and may be effective in stimulating the immune system to destroy or kill the tumor. Vaccines made from peptides, such as poly-ICLC, may also help the body build an effective immune response to kill tumor cells. Neoantigen-based glioblastoma vaccine and poly-ICLC may help the immune system to recognize and kill tumor cells.